Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends Indicate Global Improvement in Cancer Survival

February 2, 2018
By Mark L. Fuerst
Article

The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some lethal cancers.

The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some of the more lethal cancers, such as liver and lung.

The CONCORD-3 study analyzed individual patient records from 322 cancer registries in 71 countries and territories to compare 5-year survival from diagnosis for more than 37.5 million adults and children with one of 18 common cancers. These cancers represent three-quarters of all cancers diagnosed worldwide every year between 2000 and 2014. The researchers published their results in the Lancet.

“Continuous monitoring of global trends in cancer survival is crucial to assess the overall effectiveness of health systems worldwide, and to help policy-makers plan better strategies for cancer control. But, inadequate or unreliable data prevent governments from understanding the true nature and magnitude of the public health problems created by the growing cancer burden. This leaves governments poorly equipped to develop national cancer plans that will translate into real improvements in survival for patients,” said lead author Claudia Allemani, PhD, of the Cancer Survival Group at the London School of Hygiene & Tropical Medicine.

For most cancers, 5-year net survival remains the highest in the world in the United States, Canada, Australia, New Zealand, Finland, Iceland, Norway, and Sweden. In some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung, which are some of the more lethal cancers.

Survival for most cancers remains highest in a handful of countries. For women diagnosed with breast cancer in the United States and Australia, the 5-year survival rate is 90% compared with 66% for women diagnosed in India. Within Europe, the 5-year breast cancer survival rate increased to 85% or more in 16 countries, as compared with a low of 71% in Russia.

For gastrointestinal cancers, the highest levels of 5-year survival are seen in Southeast Asia. This could be due to long-standing population-based endoscopic screening programs. By contrast, in the same region, survival is generally lower than elsewhere for melanoma of the skin and for both lymphoid and myeloid malignancies.

Not all major cancers have seen large improvements. Even in 2014, pancreatic cancer remained highly lethal in all countries, with 5-year survival typically less than 15%.

A wide gulf in survival exists for childhood cancers. Five-year survival rates for acute lymphoblastic leukemia ranged from higher than 90% in Canada, the United States, and nine European countries to below 60% in China, Mexico, and Ecuador. For brain tumors, 5-year survival rates in children are higher than for adults, but range widely globally, from 28.9% in Brazil to nearly 80% in Sweden and Denmark.

The researchers noted that cancer registries should be given adequate resources to register all patients and to link the registry data to up-to-date death records. “Governments must recognize cancer registries as efficient public health instruments that produce a continuous stream of valuable information on both the impact of cancer prevention strategies and the effectiveness of health systems, and at very low cost,” they concluded.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Pivotal Presentations That May Shape the Breast Cancer Standard of Care
The Role of Molecular Testing in Ovarian Cancer Care
The Role of Molecular Testing in Ovarian Cancer Care
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Managing Expectations: Adverse Events With Melanoma Immunotherapy
Managing Expectations: Adverse Events With Melanoma Immunotherapy
2 experts in this video
NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Ashling Wahner
June 3rd 2025
Article

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.


Daratumumab Plus KRd May Be a New SOC Option in NDMM

Daratumumab Plus KRd May Be a New SOC Option in NDMM

Tim Cortese
June 3rd 2025
Article

Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.

Related Content
Advertisement

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Ashling Wahner
June 3rd 2025
Article

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.


Daratumumab Plus KRd May Be a New SOC Option in NDMM

Daratumumab Plus KRd May Be a New SOC Option in NDMM

Tim Cortese
June 3rd 2025
Article

Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.

Advertisement
Advertisement
Advertisement
Advertisement
x
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.